HUP0402264A3 - Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines process for preparing them, pharmaceutical compositions containing them and use thereof - Google Patents
Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines process for preparing them, pharmaceutical compositions containing them and use thereofInfo
- Publication number
- HUP0402264A3 HUP0402264A3 HU0402264A HUP0402264A HUP0402264A3 HU P0402264 A3 HUP0402264 A3 HU P0402264A3 HU 0402264 A HU0402264 A HU 0402264A HU P0402264 A HUP0402264 A HU P0402264A HU P0402264 A3 HUP0402264 A3 HU P0402264A3
- Authority
- HU
- Hungary
- Prior art keywords
- aminopyridines
- dicyano
- thio
- phenyl
- substituted
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10160661 | 2001-12-11 | ||
DE10160661.3 | 2001-12-11 | ||
DE10238113A DE10238113A1 (de) | 2001-12-11 | 2002-08-21 | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
DE10238113.5 | 2002-08-21 | ||
PCT/EP2002/013432 WO2003053441A1 (de) | 2001-12-11 | 2002-11-28 | Substituierte 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre verwendung |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP0402264A2 HUP0402264A2 (hu) | 2005-02-28 |
HUP0402264A3 true HUP0402264A3 (en) | 2010-03-29 |
HU230059B1 HU230059B1 (hu) | 2015-06-29 |
Family
ID=26010753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0402264A HU230059B1 (hu) | 2001-12-11 | 2002-11-28 | Szubsztituált 2-tio-3,5-diciano-4-fenil-6-aminopiridinek, előállításuk, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
Country Status (34)
Country | Link |
---|---|
US (2) | US7109218B2 (hu) |
EP (1) | EP1455785B1 (hu) |
JP (1) | JP4542778B2 (hu) |
KR (1) | KR100958474B1 (hu) |
CN (1) | CN100522945C (hu) |
AR (2) | AR037477A1 (hu) |
AT (1) | ATE424202T1 (hu) |
AU (1) | AU2002358055B2 (hu) |
BR (1) | BR0214870A (hu) |
CA (1) | CA2469586C (hu) |
CO (1) | CO5590927A2 (hu) |
CY (1) | CY1109063T1 (hu) |
DE (2) | DE10238113A1 (hu) |
DK (1) | DK1455785T3 (hu) |
ES (1) | ES2321387T3 (hu) |
HK (1) | HK1078266A1 (hu) |
HR (1) | HRP20040618B1 (hu) |
HU (1) | HU230059B1 (hu) |
IL (2) | IL162266A0 (hu) |
MA (1) | MA26348A1 (hu) |
MX (1) | MXPA04005624A (hu) |
MY (1) | MY134892A (hu) |
NZ (1) | NZ533384A (hu) |
PE (1) | PE20030694A1 (hu) |
PL (1) | PL208627B1 (hu) |
PT (1) | PT1455785E (hu) |
RU (1) | RU2315757C9 (hu) |
SI (1) | SI1455785T1 (hu) |
SV (1) | SV2004001432A (hu) |
TW (1) | TWI333487B (hu) |
UA (1) | UA77730C2 (hu) |
UY (1) | UY27571A1 (hu) |
WO (1) | WO2003053441A1 (hu) |
ZA (1) | ZA200404566B (hu) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19962924A1 (de) * | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE10110754A1 (de) * | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10110747A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
DE10129725A1 (de) * | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
DE10238113A1 (de) * | 2001-12-11 | 2003-06-18 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
DE10300111A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
TWI346109B (en) | 2004-04-30 | 2011-08-01 | Otsuka Pharma Co Ltd | 4-amino-5-cyanopyrimidine derivatives |
DE102004032651A1 (de) * | 2004-07-06 | 2006-02-16 | Bayer Healthcare Ag | Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen |
DE102004042607A1 (de) | 2004-09-03 | 2006-03-09 | Bayer Healthcare Ag | Substituierte Phenylaminothiazole und ihre Verwendung |
DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
EP1685841A1 (en) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
CA2602514A1 (en) * | 2005-03-24 | 2006-09-28 | Bayer Healthcare Ag | Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damage |
DE102005045518A1 (de) * | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung |
DE102005047558A1 (de) * | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen |
DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
EP1934208B1 (de) | 2005-10-04 | 2011-03-23 | Bayer Schering Pharma Aktiengesellschaft | Neue polymorphe form von 5-chlor-n-({ ( 5s )-2-0x0-3-[4-( 3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl} -methyl)-2-thiophencarboxamid |
JP5201817B2 (ja) * | 2005-10-28 | 2013-06-05 | 大塚製薬株式会社 | 医薬組成物 |
WO2007073855A1 (en) * | 2005-12-23 | 2007-07-05 | Bayer Healthcare Ag | Use of adenosine a1 receptor agonists for the protection of renal cells against toxic effects caused by aminoglycosides during treatment of infectious diseases |
DE102006009813A1 (de) * | 2006-03-01 | 2007-09-06 | Bayer Healthcare Ag | Verwendung von A2b/A1 Rezeptor Agonisten zur Modulation der Lipidspiegel |
DE102006042143A1 (de) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
DE102006044696A1 (de) | 2006-09-22 | 2008-03-27 | Bayer Healthcare Ag | 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung |
DE102006051625A1 (de) * | 2006-11-02 | 2008-05-08 | Bayer Materialscience Ag | Kombinationstherapie substituierter Oxazolidinone |
DE102006056739A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
DE102006056740A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
DE102007035367A1 (de) | 2007-07-27 | 2009-01-29 | Bayer Healthcare Ag | Substituierte Aryloxazole und ihre Verwendung |
DE102007036075A1 (de) * | 2007-08-01 | 2009-02-05 | Bayer Healthcare Ag | Prodrugs und ihre Verwendung |
DE102007036076A1 (de) * | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
DE102007061763A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
DE102007061764A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
DE102008008838A1 (de) | 2008-02-13 | 2009-08-20 | Bayer Healthcare Ag | Cycloalkoxy-substituierte 4-Phenyl-3,5-dicyanopyridine und ihre Verwendung |
DE102008013587A1 (de) * | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
EP2297104B1 (de) * | 2008-05-29 | 2013-08-07 | Bayer Intellectual Property GmbH | 2-alkoxy-substituierte dicyanopyridine und ihre verwendung |
DE102008062566A1 (de) * | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Aminosäureester-Prodrugs und ihre Verwendung |
DE102008062567A1 (de) * | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
AU2015272011C1 (en) * | 2009-01-29 | 2017-12-14 | Bayer Intellectual Property Gmbh | Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof |
DE102009006602A1 (de) * | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
DE102009022894A1 (de) * | 2009-05-27 | 2010-12-02 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Piperidine |
DE102010030688A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dicyanopyridine und ihre Verwendung |
US20120058983A1 (en) | 2010-09-02 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension |
EP3079696A1 (de) * | 2013-12-12 | 2016-10-19 | Bayer Pharma Aktiengesellschaft | Adenosin a1 agonisten als arzneimittel gegen nierenerkrankungen |
CA2984984A1 (en) * | 2015-05-06 | 2016-12-01 | Bayer Pharma Aktiengesellschaft | Process for the preparation of 2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}ethyl-l-alanyl-l-alaninate monohydrochloride |
WO2017137528A1 (en) | 2016-02-12 | 2017-08-17 | Charité - Universitätsmedizin Berlin | Adenosine a1 receptor agonist for use in treatment of status epilepticus |
WO2017216726A1 (en) * | 2016-06-13 | 2017-12-21 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyridines as inhibitors of dnmt1 |
WO2018153897A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit hcn-kanal-hemmern |
WO2018153900A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit sglt-2-hemmern |
WO2018153899A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc) |
WO2018153898A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten |
WO2018153895A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten |
WO2018219801A1 (en) | 2017-06-02 | 2018-12-06 | Bayer Pharma Aktiengesellschaft | Immediate-release extrudates |
WO2018219804A1 (en) | 2017-06-02 | 2018-12-06 | Bayer Pharma Aktiengesellschaft | Self-microemulsifying drug delivery systems |
ES2910071T3 (es) | 2018-03-08 | 2022-05-11 | Incyte Corp | Compuestos de aminopirazina diol como inhibidores de PI3K-Y |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19947154A1 (de) * | 1999-10-01 | 2001-10-04 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10110754A1 (de) * | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10115922A1 (de) | 2001-03-30 | 2002-10-10 | Bayer Ag | Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10134481A1 (de) * | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
DE10238113A1 (de) * | 2001-12-11 | 2003-06-18 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
-
2002
- 2002-08-21 DE DE10238113A patent/DE10238113A1/de not_active Withdrawn
- 2002-11-28 US US10/497,120 patent/US7109218B2/en not_active Expired - Fee Related
- 2002-11-28 JP JP2003554198A patent/JP4542778B2/ja not_active Expired - Fee Related
- 2002-11-28 IL IL16226602A patent/IL162266A0/xx unknown
- 2002-11-28 CA CA2469586A patent/CA2469586C/en not_active Expired - Fee Related
- 2002-11-28 WO PCT/EP2002/013432 patent/WO2003053441A1/de active Application Filing
- 2002-11-28 UA UA20040705600A patent/UA77730C2/uk unknown
- 2002-11-28 RU RU2004121161/04A patent/RU2315757C9/ru not_active IP Right Cessation
- 2002-11-28 NZ NZ533384A patent/NZ533384A/en not_active IP Right Cessation
- 2002-11-28 MX MXPA04005624A patent/MXPA04005624A/es active IP Right Grant
- 2002-11-28 HU HU0402264A patent/HU230059B1/hu not_active IP Right Cessation
- 2002-11-28 AT AT02791733T patent/ATE424202T1/de active
- 2002-11-28 AU AU2002358055A patent/AU2002358055B2/en not_active Ceased
- 2002-11-28 CN CNB028280210A patent/CN100522945C/zh not_active Expired - Fee Related
- 2002-11-28 SI SI200230820T patent/SI1455785T1/sl unknown
- 2002-11-28 BR BR0214870-6A patent/BR0214870A/pt not_active IP Right Cessation
- 2002-11-28 ES ES02791733T patent/ES2321387T3/es not_active Expired - Lifetime
- 2002-11-28 DK DK02791733T patent/DK1455785T3/da active
- 2002-11-28 PL PL370163A patent/PL208627B1/pl unknown
- 2002-11-28 DE DE50213336T patent/DE50213336D1/de not_active Expired - Lifetime
- 2002-11-28 KR KR1020047008956A patent/KR100958474B1/ko not_active IP Right Cessation
- 2002-11-28 EP EP02791733A patent/EP1455785B1/de not_active Expired - Lifetime
- 2002-11-28 PT PT02791733T patent/PT1455785E/pt unknown
- 2002-11-29 AR ARP020104616A patent/AR037477A1/es not_active Application Discontinuation
- 2002-12-09 MY MYPI20024603A patent/MY134892A/en unknown
- 2002-12-09 UY UY27571A patent/UY27571A1/es not_active Application Discontinuation
- 2002-12-10 SV SV2002001432A patent/SV2004001432A/es unknown
- 2002-12-10 PE PE2002001187A patent/PE20030694A1/es not_active Application Discontinuation
- 2002-12-10 TW TW091135620A patent/TWI333487B/zh not_active IP Right Cessation
-
2004
- 2004-06-01 IL IL162266A patent/IL162266A/en not_active IP Right Cessation
- 2004-06-07 MA MA27727A patent/MA26348A1/fr unknown
- 2004-06-09 ZA ZA2004/04566A patent/ZA200404566B/en unknown
- 2004-07-07 HR HRP20040618AA patent/HRP20040618B1/hr not_active IP Right Cessation
- 2004-07-09 CO CO04065404A patent/CO5590927A2/es active IP Right Grant
-
2005
- 2005-11-14 HK HK05110185.9A patent/HK1078266A1/xx not_active IP Right Cessation
-
2006
- 2006-05-30 US US11/443,693 patent/US20060217373A1/en not_active Abandoned
-
2009
- 2009-05-13 CY CY20091100509T patent/CY1109063T1/el unknown
-
2012
- 2012-11-21 AR ARP120104378A patent/AR088940A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0402264A3 (en) | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines process for preparing them, pharmaceutical compositions containing them and use thereof | |
HUP0402063A3 (en) | Indole-2-carboxamides process for producing them, pharmaceutical compositions containing them and use thereof | |
HUP0301069A3 (en) | Novel biarylcarboxamides, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0402225A3 (en) | Macrolide-compounds, process for their preparation and pharmaceutical compositions containing them | |
HUP0301187A3 (en) | Novel benzyl-piperidine-derivatives, process for their preparation and pharmaceutical compositions containing them | |
IL165977A (en) | Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same | |
HUP0401619A3 (en) | Phenethanolamine derivatives, process for their preparation and pharmaceutical composition containing them | |
HUP0203766A3 (en) | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof and pharmaceutical compositions containing them | |
HUP0303458A3 (en) | 6-substituted pyrido-pyrimidines, process for their preparation and pharmaceutical compositions containing them | |
HUP0103063A3 (en) | Novel 2h-pyridazin-3-one derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
IL162185A0 (en) | Phenylpropionate derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same | |
IL165012A0 (en) | (S)-4-Amino-5-chloro-2-methoxy-N-Ä1-(-tetrahydrofurylcarbonyl)-4-piperidinylmethylÜ-4-piperidinylÜbenzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | |
HUP0301817A3 (en) | Kahalalide compounds, process for preparing thereof, pharmaceutical compositions comprising them and their use | |
HUP0400040A2 (hu) | Szulfonamidok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HU0100489D0 (en) | New piperidine-4-sulphonamide compounds, process for their preparation and pharmaceutical compositions containing them | |
HUP0401107A3 (en) | Novel benzo-fused heterocycles, their use process for their preparation and pharmaceutical compositions containing them | |
HUP0201785A3 (en) | Dihydrobenzodiazepins, process for producing them, their use and pharmaceutical compositions containing them | |
HUP0302515A3 (en) | Sulfanidothienopyrimidines, process for their preparation and pharmaceutical compositions containing them | |
HUP0401082A3 (en) | Substituted 4-aminocyclohexanols, process for their preparation and pharmaceutical compositions containing them | |
HUP0302429A3 (en) | 4-amino-quinazolines, process for producing them, pharmaceutical compositions containing them and their use | |
AU2003231920A8 (en) | Antiinfectve compounds, process for their preparation and pharmaceutical compositions containing them | |
HUP0303105A3 (en) | Novel aminocyclohexane derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0204394A3 (en) | Tetrahydropyridines, process for their preparation, pharmaceutical compositions containing them and use thereof | |
HUP0401829A3 (en) | Substituted (1h)-quinoxalin-2-one compounds and substituted 4-aryl- or 4-heteroarylcyclohexane compounds, process for their preparation and pharmaceutical compositions containing the (1h)-quinoxalin-2-one compounds | |
HUP0500958A3 (en) | 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them, therapeutic use thereof and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB9A | Succession in title |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE Free format text: FORMER OWNER(S): BAYER HEALTHCARE AG., DE |
|
GB9A | Succession in title |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Free format text: FORMER OWNER(S): BAYER HEALTHCARE AG., DE; BAYER PHARMA AKTIENGESELLSCHAFT, DE; BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE |
|
HC9A | Change of name, address |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Free format text: FORMER OWNER(S): BAYER HEALTHCARE AG., DE; BAYER PHARMA AKTIENGESELLSCHAFT, DE; BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE |
|
MM4A | Lapse of definitive patent protection due to non-payment of fees |